118 Chapter 5 p = 0.035 0.022 0.26 −10 −5 0 5 10 CDO1 methylation p = 0.48 p = 0.26 p = 0.79 p = 0.012 0.004 0.15 p = 0.20 −10 −5 0 5 10 GHSR methylation p = 0.09 p = 0.012 0.018 0.024 p = 0.26 p = 0.23 p = 0.007 0.008 0.91 −10 −5 0 5 10 MAL methylation p = 0.002 0.001 0.26 p = 0.0502 p = 0.54 p = 0.53 diagnosis Control Benign Malignant p = 0.019 0.008 0.71 −5 0 5 10 C2CD4D methylation Full void urine p = 0.076 Urine supernatant p = 0.29 Urine sediment p = 0.86 Self−sample p = 0.002 0.001 0.14 Cervical scrape n=29 n=22 n=28 n=29 n=25 n=29 n=30 n=25 n=28 n=40 n=22 n=24 n=40 n=24 n=28 n=30 n=22 n=28 n=29 n=25 n=28 n=30 n=24 n=27 n=40 n=22 n=24 n=40 n=24 n=28 n=29 n=22 n=28 n=29 n=25 n=29 n=30 n=25 n=28 n=40 n=22 n=24 n=40 n=24 n=28 n=29 n=22 n=28 n=29 n=25 n=29 n=30 n=25 n=28 n=40 n=22 n=24 n=40 n=24 n=28 Figure 1: Methylation analysis in patient-friendly sample types. Methylation levels of most discriminating markers C2CD4D, CDO1, GHSR, and MAL in full void (unfractionated) urine, urine supernatant, urine sediment, cervicovaginal self-samples, and clinician-taken cervical scrapes of healthy controls and patients diagnosed with a benign or malignant ovarian mass. Methylation levels are expressed by 2log-transformed Cq ratios and bold circles represent medians. DNA methylation levels are correlated between paired cervical scrapes and urine samples DNA methylation levels of genes significantly discriminating between healthy and malignant in cervical scrapes and urine (i.e. C2CD4D, CDO1, GHSR, MAL) were compared
RkJQdWJsaXNoZXIy MjY0ODMw